|

89Zr-Patritumab deruxtecan Clinical Trials

1 actively recruiting trial

Also known as: Tracer

Pipeline

Phase 2: 1

Top Sponsors

  • The Netherlands Cancer Institute1

Indications

  • Advanced Non-Small Cell Squamous Lung Cancer1
  • Non-Small Cell Lung Carcinoma1
  • Lung Cancer1
  • EGFR Gene Mutation1
  • Cancer1

Other1 trial

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.